Zai Lab Ltd ADR (ZLAB) Stock Price, Quote & News

Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for commu...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 21 6163 2588

Website: www.zailaboratory.com

Address:

Building B, 899 Halei Road, Pudong, China

Quantumup Sep. 8 at 10:25 AM

Citizens⬆️ $IDYA's PT to $45 from $41, reiterated at a Market Outperform and said, IDEAYA Biosciences's partner Hengrui showed strong numbers with DLL3-ADC IDE849 (SHR4849) in updated Ph1 data in Chinese patients that cleared the hurdle with more room than anticipated. $AZN $RHHBY $BMY $ZLAB ABBV Citizens added, IDE849 checked all the boxes and showed best-in-class efficacy as well as duration compared to the competitive landscape (details inside). We point to $IDYA's R&D day on Monday morning for more details and we expect the stock to react positively (+10%) on this strong update. We maintain our Market Outperform rating and increase our DCF-derived price target to $45 from $41 based on an increased probability of success (25% from 15%) for IDE849.

0 · Reply

Quantumup Sep. 4 at 12:56 PM

Barclays🏁 $IDYA Overweight/$40. Citizens🏁 $IDYA Market Outperform/$41. $ZLAB $AMGN $DSNKY $PFE GILD AZN RHHBY Barclays and Citizens JMP said in their initiation reports:

0 · Reply

StocktwitsNews Sep. 3 at 3:15 PM

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug $ZLAB $AMGN https://stocktwits.com/news/equity/markets/zai-lab-to-await-more-trial-data-before-filing-for-regulatory-approval-for-experimental-cancer-drug/chwcTXURd8U

0 · Reply

KingThoth509 Sep. 2 at 12:35 PM

$ZLAB $35 on deck!

0 · Reply

KingThoth509 Sep. 2 at 12:35 PM

$ZLAB News out ...new drug approval. Should definitely gap up today

0 · Reply

lucgallo Sep. 2 at 4:46 AM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-approval-tivdakr-patients-recurrent-or/

0 · Reply

KingThoth509 Aug. 29 at 3:07 PM

$ZLAB $40 target mid september

0 · Reply

SodApOp_PIMPski Aug. 28 at 2:19 PM

$ZLAB gap officially closed

0 · Reply

lucgallo Aug. 25 at 9:35 AM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/argenx-announces-positive-topline-results-adapt-seron-study/

0 · Reply

SodApOp_PIMPski Aug. 21 at 10:48 PM

$ZLAB the gap and 200dma meeting at 31.70s. Buy order open gtc at 31.90

0 · Reply

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

Aug 28, 2025, 7:30 AM EDT - 12 days ago

Zai Lab Announces Participation in Investor Conferences in September 2025

Aug 19, 2025, 7:30 AM EDT - 21 days ago

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Aug 13, 2025, 11:00 AM EDT - 27 days ago

Zai Lab Establishes Oncology Scientific Advisory Board

Aug 7, 2025, 10:29 PM EDT - 4 weeks ago

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:00 AM EDT - 4 weeks ago

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 10, 2025, 7:30 AM EDT - 2 months ago

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

Jun 30, 2025, 9:05 AM EDT - 2 months ago

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Jun 13, 2025, 7:00 AM EDT - 3 months ago

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Jun 2, 2025, 7:00 AM EDT - 3 months ago

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 3 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NVCR

May 30, 2025, 7:30 AM EDT - 3 months ago

Zai Lab Announces Participation in Investor Conferences in June 2025

May 28, 2025, 2:48 AM EDT - 3 months ago

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 22, 2025, 11:25 AM EDT - 3 months ago

Zai Lab Limited: Banking On Chinese Pharma Growth

May 19, 2025, 7:00 AM EDT - 4 months ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

May 11, 2025, 8:55 AM EDT - 4 months ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:00 AM EDT - 4 months ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Apr 25, 2025, 1:12 PM EDT - 4 months ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Apr 23, 2025, 10:56 AM EDT - 4 months ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Apr 21, 2025, 7:30 AM EDT - 5 months ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Mar 26, 2025, 7:00 AM EDT - 5 months ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Mar 21, 2025, 5:16 PM EDT - 6 months ago

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Mar 20, 2025, 1:05 PM EDT - 6 months ago

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 12, 2025, 7:30 PM EDT - 6 months ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Mar 3, 2025, 7:30 AM EST - 6 months ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Feb 27, 2025, 10:46 PM EST - 6 months ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 6 months ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Jan 28, 2025, 7:30 AM EST - 8 months ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Jan 22, 2025, 11:15 PM EST - 8 months ago

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Jan 17, 2025, 7:30 AM EST - 8 months ago

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Jan 15, 2025, 7:30 AM EST - 8 months ago

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Jan 10, 2025, 7:30 AM EST - 8 months ago

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

VRTX

Jan 10, 2025, 7:30 AM EST - 8 months ago

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

VRTX

Jan 9, 2025, 6:30 PM EST - 8 months ago

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Dec 26, 2024, 2:31 PM EST - 9 months ago

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 12, 2024, 7:30 AM EST - 9 months ago

Zai Lab Announces Participation in Investor Conference in January 2025

Dec 2, 2024, 7:02 AM EST - 10 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

NVCR

Nov 27, 2024, 11:05 PM EST - 10 months ago

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List

Nov 21, 2024, 4:00 AM EST - 10 months ago

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

PFE

Nov 18, 2024, 9:15 AM EST - 10 months ago

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Nov 14, 2024, 7:43 PM EST - 10 months ago

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Nov 13, 2024, 4:12 PM EST - 10 months ago

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Nov 12, 2024, 11:53 AM EST - 10 months ago

Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 6:30 AM EST - 10 months ago

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 11, 2024, 7:30 AM EST - 10 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ARGX

Oct 29, 2024, 7:30 AM EDT - 11 months ago

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Oct 24, 2024, 5:15 AM EDT - 11 months ago

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Oct 18, 2024, 7:30 AM EDT - 11 months ago

Zai Lab Announces Participation in November and December Investor Conferences

Oct 17, 2024, 8:00 AM EDT - 11 months ago

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Quantumup Sep. 8 at 10:25 AM

0 · Reply

Quantumup Sep. 4 at 12:56 PM

Barclays🏁 $IDYA Overweight/$40. Citizens🏁 $IDYA Market Outperform/$41. $ZLAB $AMGN $DSNKY $PFE GILD AZN RHHBY Barclays and Citizens JMP said in their initiation reports:

0 · Reply

StocktwitsNews Sep. 3 at 3:15 PM

0 · Reply

KingThoth509 Sep. 2 at 12:35 PM

$ZLAB $35 on deck!

0 · Reply

KingThoth509 Sep. 2 at 12:35 PM

$ZLAB News out ...new drug approval. Should definitely gap up today

0 · Reply

lucgallo Sep. 2 at 4:46 AM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-approval-tivdakr-patients-recurrent-or/

0 · Reply

KingThoth509 Aug. 29 at 3:07 PM

$ZLAB $40 target mid september

0 · Reply

SodApOp_PIMPski Aug. 28 at 2:19 PM

$ZLAB gap officially closed

0 · Reply

lucgallo Aug. 25 at 9:35 AM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/argenx-announces-positive-topline-results-adapt-seron-study/

0 · Reply

SodApOp_PIMPski Aug. 21 at 10:48 PM

$ZLAB the gap and 200dma meeting at 31.70s. Buy order open gtc at 31.90

0 · Reply

Quantumup Aug. 20 at 3:56 PM

Piper Sandler (Aug. 18)🏁 $NUVL at an Overweight/$112. $RHHBY $PFE TAK NVS ABBV LLY JNJ $ZLAB $NUVB Piper Sandler said in its initiation report: Investors largely view $NUVL as a high quality precision oncology company but seem to be in a waiting pattern until we get closer to the 1L ALK data in a few years. We think the Street underestimates the near-term value creation over the next 18 months as we get (1) updated Ph II neladalkib data in 2L+ ALK NSCLC later this year which will confirm the degree of differentiation vs. lorlatinib, and by indirect comparison vs. alectinib, (2) initial commercial sales from zidesamtinib in 2026 in the ROS1 market which we think investors undervalue, and 3) potential initial data for NVL-330 in HER2+ NSCLC next year, in our view.

0 · Reply

FannyPackin Aug. 13 at 1:39 AM

$ZLAB need some more patience here, trimmed 5-10% month or so ago when position got too heavy.. wen 50’s?

0 · Reply

smartkarma Aug. 12 at 3:46 AM

$ZLAB | [Zai LAB (ZLAB US, BUY, TP US$40) Review]: Past Is Holding ZLAB Back but Future Is What Matters "Zai Lab reports better-than-expected financials but faces challenges with competition and slow product ramp-up. Despite concerns, upcoming catalysts keep analysts optimistic with a BUY rating." - Eric Wen (Blue Lotus Research Institute) Read more: https://www.smartkarma.com/insights/zai-lab-zlab-us-buy-tp-us-40-review-past-is-holding-zlab-back-but-future-is-what-matters

0 · Reply

erevnon Aug. 11 at 1:39 PM

Citigroup maintains Zai Lab $ZLAB at Buy and raises the price target from $66 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Aug. 11 at 1:16 PM

Citigroup updates rating for Zai Lab ( $ZLAB ) to Buy, target set at 66 → 69.

0 · Reply

jonny500 Aug. 7 at 3:59 PM

$ZLAB Earnings looked OK to me.

1 · Reply

SodApOp_PIMPski Aug. 7 at 1:35 PM

$ZLAB 29 buy order open

1 · Reply

OpenOutcrier Aug. 7 at 12:33 PM

$ZLAB (-6.5% pre) Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates https://ooc.bz/l/73086

0 · Reply

Pika_Capital Aug. 7 at 11:19 AM

$ZLAB very weak quarter and they are still lying about full year guidance lol. I'm out for now. My patience threshold is very low nowadays to give you more chances. At least made some money here.

1 · Reply

BambooC Aug. 5 at 2:47 PM

$LKNCY $ZLAB come on even zlab is pushing for 40

0 · Reply

SodApOp_PIMPski Jul. 30 at 1:39 PM

$ZLAB gap filled 🎯🎯🎯

1 · Reply

RayRex123 Jul. 29 at 7:36 PM

$ZLAB Still waiting

0 · Reply

Market Cap	3.44B
Revenue (ttm)	398.99M
Net Income (ttm)	-257.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-64.44%
Debt to Equity Ratio	0.22

Volume	1,411,400
Avg Vol	704,772
Day's Range	N/A - N/A
Shares Out	111.76M
Stochastic %K	44%
Beta	1.04
Analysts	Strong Sell
Price Target	$56.50